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Biologically active peptides
INTRODUCTION 
Therapeutics, e.g. oncology (buserelin)
Processing hot melt extrusion (HME)
1. High temperature exposure  OBJECTIVE





Stability indicating UPLC method: Dry heat conditions Kinetic data evaluation
Acquity BEH300 C18 1.7µm (2.1 ×100 mm) T (°C) 150 157.5 165 172.5 180 •Statistical evaluation of 17 solid-state
kinetic models:MF A: 95/5 H2O/ACN + formic acid
MF B: 5/95 H2O/ACN + formic acid Time (t)(min)
40 25 15 10 10
80 50 30 20 20
120 75 45 30 30
 Nucleation (7)
1.5 min isocratic hold at 100% A
linear gradient from 0 to 21% B in 9.5 min
160 100 60 40 40
 Geometrical contraction (2)
 Diffusion (4)
Detection
7 min isocratic hold  Reaction-order (4)
•Extrapolation to HME-related conditions
•DAD-UV (kinetics via normalized areas)
•MS/MS (degradant identification)
RESULTS and DISCUSSION 
Kinetic data evaluation per temperature




















































y = 1.1311x3 + 92.52x2 + 2522.4x + 22911
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Solid Molten Degradation mechanism




Polynomial regr. Linear regr. solid state





5 min 125°C <0.01% 1.33% Isomerisation* pGlu-His-Trp-Ser-Tyr-Ser(tBu)-Leu-Arg-Pro-NH-Et
CONCLUSIONS
On-going:(1)Kinetics: Ginstling-Brounshtein degradation model: HME






(4)Pharmacokinetics in-vivo: (mice subdermal)
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